Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
Palisade Bio (NASDAQ: PALI) announced the acceptance of its abstract for poster presentation at the 2025 Crohn's & Colitis Congress in San Francisco. The presentation, scheduled for February 7, 2025, will showcase research on PALI-2108, a colon-specific PDE4B inhibitor prodrug. The poster, titled 'PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model,' will be presented during the Poster and Exhibition Hall Reception at Moscone West.
Palisade Bio (NASDAQ: PALI) ha annunciato l'accettazione del suo abstract per la presentazione su poster al 2025 Crohn's & Colitis Congress a San Francisco. La presentazione, programmata per il 7 febbraio 2025, mostrerà la ricerca su PALI-2108, un pro-farmaco inibitore della PDE4B specifico per il colon. Il poster, intitolato 'PALI-2108, un pro-farmaco inibitore della PDE4B specifico per il colon è attivato nel colon e riduce i sintomi della colite ulcerosa in un modello murino di colite acuta DSS,' sarà presentato durante la Reception nel Poster e Exhibition Hall al Moscone West.
Palisade Bio (NASDAQ: PALI) anunció la aceptación de su resumen para la presentación en poster en el 2025 Crohn's & Colitis Congress en San Francisco. La presentación, programada para el 7 de febrero de 2025, mostrará la investigación sobre PALI-2108, un pro-fármaco inhibidor específico de PDE4B para el colon. El poster, titulado 'PALI-2108, un pro-fármaco inhibidor de PDE4B específico para el colon se activa en el colon y reduce los síntomas de colitis ulcerosa en un modelo de ratón de colitis aguda DSS,' será presentado durante la recepción en el Hall de Posters y Exposición en Moscone West.
팔리세이드 바이오 (NASDAQ: PALI)는 샌프란시스코에서 열리는 2025 크론병 및 궤양성 대장염 학회에서 포스터 발표를 위한 초록이 수락되었음을 발표했습니다. 2025년 2월 7일로 예정된 이 발표에서는 PALI-2108, 대장 특이적 PDE4B 억제제 프로약물에 대한 연구를 선보일 것입니다. 'PALI-2108, 대장 특이적 PDE4B 억제제 프로약물, 대장에서 활성화되고 급성 대장염 DSS 쥐 모델에서 궤양성 대장염 증상을 감소시킵니다.'라는 제목의 포스터는 Moscone West의 포스터 및 전시 홀 리셉션에서 발표될 예정입니다.
Palisade Bio (NASDAQ: PALI) a annoncé l'acceptation de son résumé pour une présentation par affiche au 2025 Crohn's & Colitis Congress à San Francisco. La présentation, prévue pour le 7 février 2025, mettra en avant des recherches sur PALI-2108, un pro-médicament inhibiteur de la PDE4B spécifique au côlon. L'affiche, intitulée 'PALI-2108, un pro-médicament inhibiteur de la PDE4B spécifique au côlon est activé dans le côlon et réduit les symptômes de la colite ulcéreuse dans un modèle murin de colite aiguë DSS,' sera présentée lors de la réception dans la salle des affiches et des expositions au Moscone West.
Palisade Bio (NASDAQ: PALI) hat die Annahme seines Abstracts für die Posterpräsentation beim 2025 Crohn's & Colitis Congress in San Francisco bekannt gegeben. Die Präsentation, die für den 7. Februar 2025 geplant ist, wird Forschung zu PALI-2108, einem colon-spezifischen PDE4B-Inhibitor-Prodrug, vorstellen. Das Poster mit dem Titel 'PALI-2108, ein colon-spezifisches PDE4B-Inhibitor-Prodrug, das im Colon aktiviert wird und die Symptome der ulcerativen Kolitis in einem akuten Kolitis-DSS-Mausmodell reduziert,' wird während der Empfangsveranstaltung im Poster- und Ausstellungsbereich im Moscone West präsentiert.
- Acceptance of research for presentation at a major industry congress indicates scientific validation of PALI-2108 development
- Preclinical data shows PALI-2108 reduces ulcerative colitis symptoms in mouse model
- None.
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that its abstract has been accepted for poster presentation at the Crohn’s & Colitis Congress being held February 6-8, 2025 in San Francisco, CA.
Details of the poster presentation are as follows:
Session: Poster and Exhibition Hall Reception
Poster Title: PALI-2108, a Colon-Specific PDE4B Inhibitor Prodrug is Activated in the Colon and Reduces Ulcerative Colitis Symptoms in an Acute Colitis DSS Mouse Model
Session Dates and Times: February 7, 2025 from 5:00 PM to 6:30 PM PST
Presentation Location: Level 1 – Exhibition Hall – Moscone West
For more information about the congress, please visit crohnscolitiscongress.org.
About Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The Company believes that by using a targeted approach with its novel therapeutics it will transform the treatment landscape. For more information, please go to www.palisadebio.com.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
PALI@jtcir.com
FAQ
What is PALI-2108 and how does it work in treating ulcerative colitis?
When and where will Palisade Bio present their PALI-2108 research at the 2025 Crohn's & Colitis Congress?
What are the key findings from Palisade Bio's PALI-2108 preclinical studies?
How might the presentation at the 2025 Crohn's & Colitis Congress impact PALI stock?
